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Abstract
The presentation of microbial protein antigens by Major Histocompatibility Complex (MHC) molecules is essential for the
development of acquired immunity to infections. However, most biochemical studies of antigen processing and
presentation deal with a few relatively inert non-microbial model antigens. The bacterial pore-forming toxin listeriolysin O
(LLO) is paradoxical in that it is cytotoxic at nanomolar concentrations as well as being the source of dominant CD4 and CD8
T cell epitopes following infection with Listeria monocytogenes. Here, we examined the relationship of LLO toxicity to its
antigenicity and immunogenicity. LLO offered to antigen presenting cells (APC) as a soluble protein, was presented to CD4 T
cells at picomolar to femtomolar concentrations- doses 3000–7000-fold lower than free peptide. This presentation required
a dose of LLO below the cytotoxic level. Mutations of two key tryptophan residues reduced LLO toxicity by 10–100-fold but
had no effect on its presentation to CD4 T cells. Thus there was a clear dissociation between the cytotoxic properties of LLO
and its very high antigenicity. Presentation of LLO to CD8 T cells was not as robust as that seen in CD4 T cells, but still
occurred in the nanomolar range. APC rapidly bound and internalized LLO, then disrupted endosomal compartments within
4 hours of treatment, allowing endosomal contents to access the cytosol. LLO was also immunogenic after in vivo
administration into mice. Our results demonstrate the strength of LLO as an immunogen to both CD4 and CD8 T cells.
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Introduction
LLO is an immunological enigma: it is both a major virulence
determinant and a major immunogen following L. monocytogenes
infection, yet it is a highly cytotoxic protein. LLO, a member of
the cholesterol-dependent cytolysin (CDC) family of bacterial
toxins [1,2], is a pore-forming protein, capable of lysing red blood
cells, and inducing necrotic, pyroptotic, and apoptotic forms of cell
death in nucleated cells [3–8]. Intracellular L. monocytogenes requires
LLO to escape the phagosome and survive in infected cells. LLO-
deficient L. monocytogenes (Dhly) are not pathogenic and are poorly
immunogenic even at high doses [9–12]. LLO production is
carefully controlled by the microbe, through both transcriptional
and post-translational mechanisms to prevent the early destruction
of the infected cell [13–15]. L. monocytogenes engineered to have
uncontrolled LLO activity are less virulent because they destroy
their protective host niche [16].
During infection with L. monocytogenes a CD4 and CD8 T cell
response is directed to LLO [9,17–20]. Moreover, DNA vaccines
containing LLO sequences fused to tumor-associated antigen
induce specific immune responses to tumors [21]. In brief, LLO is
immunogenic when presented as part of microbes or DNA
vaccines. Yet, in vivo as well as in culture assays, LLO is a strong
apoptogenic protein that causes the death of T cells as they
became activated, thereby inhibiting their responses [22].
Additionally, purified LLO causes cell death in dendritic cells
(DC) [7]. LLO tested as a purified protein in culture assays is
poorly immunogenic causing marked negative effects on cells
[17,23].
In this work, we attempt to explain these apparently
contradictory issues regarding LLO antigenicity and immunoge-
nicity focusing on its effects on APC and the T cell response. We
found LLO to be one of the strongest generators of CD4 T cell
responses we have tested. It elicited CD4 T cell responses at
unprecedented [fM]/[pM] levels, approximately 3000–7000 times
more efficiently than the responses to the cognate peptide. LLO
was also presented to CD8 T cells. Importantly, the immunogenic
and cytotoxic activities of LLO were distinct because LLO
mutants having much reduced cytotoxicity were processed and
presented equivalently to the wild-type protein and elicited in vivo
immune responses. The parameters of LLO binding, uptake, and
catabolism by APC, as well as breakdown of endosomal vesicles
were included in this evaluation.
Results
Cytotoxicity of LLO
We examined the antigenicity of soluble LLO (referred to as
LLOWT) as well as of LLO having two key tryptophans
mutagenized to alanines [24]. These residues are part of a highly
conserved undecapeptide sequence (483-ECTGLAWEWWR-493)
involved in the pre-pore to pore transition when CDC family
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members bind to membranes [25]. Mutation of the tryptophans to
alanines at both residues 491 and 492 (LLOWW), or at only
residue 492 (LLO492A) led to a reduction in hemolytic activity of
,95–99.5% (Fig. 1A) and in cytolytic activity to nucleated cells
(Fig. 1B). Also, LLO inhibited responses of primary T cells in a
dose dependent manner (Fig. 1C).
The concentration of LLO required to induce cell death in DCs
and macrophages was examined. Bone marrow-derived DCs
(BMDC) (Fig. 1D–H) and bone marrow-derived macrophages
(BMM) (not shown) were treated with different concentrations of
LLOWT, LLOW492A, or LLOWW for 6 hours, and cell death
was measured using Annexin V/7-AAD (Fig. 1D–E), JC-1
(Fig. 1F), Red-VAD (pan-caspase; Fig. 1G), and Red-DEVD
(caspase-3; Fig. 1H) staining. All four assays showed apoptosis of
BMDC and BMM at ,1 nM of LLOWT while the LLOW492A
and LLOWW induced apoptosis between 10 and 100 nM. The
dose of LLOWT required for cell death coincided with the drop in
the T cell response detected in our T cell assays (see below).
The mechanisms of cell death induced by LLO are not entirely
understood. LLO is an endosomolytic agent that can cause cell
Figure 1. Reduced toxicity of LLO tryptophan mutants. A. LLOWW was tested for hemolytic activity on human red blood cells as in [46]. LLO
was added at the indicated concentrations for 60 min. at 37uC then, hemoglobin release was measured at OD570. B. C3.F6 [52] cell line was
incubated with the indicated concentrations of LLOWT or LLOWW for 1 hr. at 37uC. Cells were stained with trypan blue and percentage of live cells
(trypan negative) was determined. C. An ovalbumin-responsive primary T cell line (56104) [6] was incubated for 16 hr. with BMDC (56104) and the
indicated concentrations of ovalbumin (antigen) and LLO (toxin). T cell responses were measured by IL-2 production. D-H. BMDC (16106) were
treated with the indicated LLO variants at the given concentrations for 6 hours. Cell death was measured by (D–E) Annexin V/7-AAD staining, (F) JC-1
dye, (G) Red-VAD, or (H) Red-DEVD. All cell death analyses were performed by flow cytometry. Cells were gated for CD11c+ events then the
percentage of affected CD11c+ cells was plotted. Results in (A–C) are representative of two independent experiments. Bars in (D–H–F) represent the
mean6S.D. of at least 2 independent experiments performed in duplicate or triplicate (n = 5–7).
doi:10.1371/journal.pone.0032310.g001
LLO as an Immunogen
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death from within a cell by releasing intracellular stores of
granzymes [6,26]. Based on this information APC were examined
for release of intracellular endosomal contents. Fluorescein-labeled
low molecular weight dextrans (3 kDa) were given to BMM, and
then examined with or without LLO treatment. Untreated cells
displayed a mostly punctate green staining corresponding to
previously reported endosomal localization of the dextrans
(Fig. 2A, D, G) [27]. Approximately 80% of dextran-labeled
untreated cells contained punctate vesicular staining with no
diffuse cytosolic staining (Fig. 2A). ImageJ was used to count both
the number of particles (puncta) per field and the pixel size of the
particles (Fig. 2B–C). Following 4 hr. of LLOWT treatment,
cellular morphology was altered, and ,20% of the cells had a
punctate staining, while ,80% showed the diffuse patterns shown
in Fig. 2E, H. We also detected an increase in the size of FITC-
Dextran+ compartments present in LLOWT treated cells (Fig. 2C).
LLOWW did not cause an obvious change in the cellular
morphology, but still led to ,60% of the cells possessing a
cytosolic distribution of dextran and reduced number of puncta as
well as increased particle size (Fig. 2B–C, F, I). These data show
that LLO releases endosomal contents into the cytosol, providing a
possible mechanism for entry of endocytosed antigens into the
class I MHC processing pathway, discussed below.
Processing and presentation of LLOWT
The experiments only examine the processing and presentation
of LLO independent of the costimulatory activity of the APC. For
this, T cell hybridomas were used since their responses are
Figure 2. Release of vesicular dextrans into the cytosol. A–I. BMM (1.256105) were adhered to 12 mm coverslips and treated with FITC-
dextran for 30 min then either left untreated (D,G) or treated with LLOWT (E,H) or LLOWW (F,I) for 4 hours. A. The number of cells containing
punctate staining was determined by counting ,100 individual cells for each treatment. A cell was considered to have puncta if it had any visible
discrete spots, as in panel G. Cells were considered to have no puncta if the green staining was homogeneous, as in panel H. B–C. ImageJ analysis of
the number of particles and size of particles per field was determined as detailed in the materials and methods. Bars represent the mean+/2S.D.
particles per field (B) or pixel size of particles (C) for three independent fields with 10–24 cells per field. D–F. Representative epiluminescence images
taken following treatment with FITC-Dextran and then either left untreated (D) or treated with 1 nM LLOWT (E) or 10 nM LLOWW (F). The nucleus
(DAPI) was false colored blue and FITC-Dextran was false colored green. G–H. Representative laser scanning micrographs of FITC-dextran loaded
BMM either untreated (G) or treated with 1 nM LLOWT (H) or 10 nM LLOWW (I). Scale bars in represent 50 mm (D–F) or 10 mm (G–I). Microscopy is
representative of 2 independent experiments performed in duplicate.
doi:10.1371/journal.pone.0032310.g002
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quantitatively related to the amount of peptide-MHC complexes
presented by the APC. CD4 T cell hybridomas were generated
against the 190–201 segment of LLO [18] and tested against the
various LLO preparations.
In any given T cell assay, LLOWT was presented to CD4 T
cells at low picomolar to high femtomolar concentrations: the
presentation was ,1000–10000-fold more efficiently than the
presentation of the peptide LLO(190–201) (Fig. 3A). There was a
,20-fold improvement in presentation of LLO(185–207) over
LLO(190–201), but this effect was not responsible for the
improved presentation of LLOWT. The enhanced presentation
was found with a variety of APC, including peritoneal exudate
macrophages (PEC) (Fig. 3A), BMDC (Fig. 3B), BMM, irradiated
splenocytes, and purified splenic CD11b+ and CD11c+ cells (data
not shown). The response of T cell hybridomas was initially
detected at the 0.1–10 pM range, peaked between 10–100 pM,
and dropped at 1–10 nM. The drop corresponded to the doses
that induced cytolytic and apoptotic effects on APC and T cells
(Fig. 1) [22]. The LLO-reactive CD4 T cell hybridomas also
responded to DC infected with live L. monocytogenes at multiplicities
of infection (MOI) ranging from 0.1–5 (Fig. 3C). The enhanced
presentation of LLOWT required intact tertiary structure because
digestion with endoproteinase AspN yielded the LLO(164–204)
fragment that was presented at equivalent doses to the LLO(190–
201) peptide (Fig. 3D). LLO preparations were purified with
polymyxin B columns to remove LPS and yielded the same
enhanced antigenicity (data not shown). Tlr42/2 and Myd882/2
splenocytes presented LLOWT equivalently to wild-type counter-
parts (Fig. 3E–F), further demonstrating that LPS contamination
was not responsible for the enhanced presentation of LLO.
Treatment of LLOWT with cholesterol had no effect on its
presentation to hybridomas (data not shown).
Processing and presentation of LLO is independent of its
immediate cytotoxicity
LLOW492A and LLOWW were presented by either BMDC
(Fig. 4A–B) or BMM (not shown) at the same concentrations as
LLOWT despite requiring higher doses to induce cell death.
Fig. 4C shows the summary of 62 independent T cell assays
performed with 4 different hybridomas and either BMDC or
BMM as the APC. The mean half-maximal activation dose was
not significantly different between the three LLO protein
preparations: for LLOWT, LLOW492A, LLOWW, 3.3 pM,
7.5 pM, 4.7 pM respectively, compared to 1.2 nM, and 23 nM
for LLO(185–207) and LLO(190–201), respectively. These
amounted to an average fold-increase of presentation for
LLOWT, LLOW492A, LLOWW, and LLO(185–207) of
,7000, ,3000, ,5000, and ,20-fold respectively when com-
pared to LLO(190–201). Importantly, the doses of all three LLO
variants required to reach half-maximal activation of T cells were
.1000-fold lower than the doses required to induce cell death
(,1–10 pM versus ,1–10 nM).
We wanted to determine if LLO protein could enhance the
presentation of an ectopic antigenic specificity. A construct was
generated that contained the 45–65 segment of the hen-egg white
lysozyme (HEL) protein fused to the amino terminus of LLO.
There was a ,1000-fold enhancement in presentation of LLO-
HEL(45–65) compared to presentation of the HEL(48–62)
peptide (Fig. 4D). The response of 3A9 T cells to the HEL(48–
62) peptide and to HEL protein was identical [28]. The
Figure 3. Enhanced presentation of an LLO protein-derived CD4 T cell epitope. A–B. 56104 I-Ab-restricted LLO(190–201)-specific
hybridomas 57-3 (A) or LL73 (B) were incubated for 16 h with 105 PEC (A) or 56104 BMDC (B) from C57BL/6 mice and various concentrations of
either LLOWT, LLO(190–201), or LLO(187–205). C. BMDC (105) were infected with the indicated MOI of L. monocytogenes EGD strain as in [45] and
16 hrs. later the response of 57-3 (56104) was determined. D. LLO was treated with endoproteinase AspN or buffer for ,16 hr. at 37uC then
incubated with for ,16 hr. with 105 irradiated C57BL/6 splenocytes and 57-3 (56104). E, Tlr42/2, (F) Myd882/2 (KO), or (E–F) C57BL/6J (WT) irradiated
splenocytes (105) were treated with LLOWT or LLO(190–201) and (E) 57-11 or (F) 57-3 T cell hybridomas (56104). Following all incubations, T cell
hybridoma activation was determined by CTLL-2 assay. Points indicate the mean6S.D.
doi:10.1371/journal.pone.0032310.g003
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enhancement of presentation required that the peptide be
covalently fused to LLO because treatment of cells with LLO
and free HEL(48–62) peptide did not affect the presentation of
the peptide (data not shown).
Quantification of the uptake, binding and catabolism of
LLO
The uptake and catabolism of LLO was examined in order to
relate it to its antigenicity. LLO was labeled with 125Iodine and its
binding, uptake, and catabolism by APC was evaluated.
Radiolabeling did not affect the hemolytic activity of LLOWT,
LLOW492A, or LLOWW (data not shown). All LLO prepara-
tions bound to BMM incubated on ice, at the levels shown in
Figure 5A, ranging from 2–4% of input cpm. In contrast the
proteins HEL-125I bound to BMM at ,0.297% of input. As noted
the mutation of tryptophans reduced, but did not prevent LLO
from binding to cells. LLO-125I was internalized rapidly by BMM
(Fig. 5B) and BMDC (data not shown) following incubation at
37uC. About 40–50% of total input LLO was found as cell-
associated protein within 30 minutes. There was ,15–20%
reduction in total internalization of LLOW492A (Fig. 5B) or
LLOWW (not shown) compared to LLOWT. In contrast,
HEL-125I was internalized at ,0.8% of total input protein.
LLOWT was rapidly catabolized, with ,20% of total 125I counts
found in the TCA soluble fraction of the cell culture media within
1 hour of treatment (Fig. 5C). By 24 hr.,.80% of total 125I counts
were found in the soluble fraction. Similar rates of catabolism were
detected with LLOW492A (Fig. 5D) and LLOWW (not shown).
BMM and BMDC were fixed at different times following
treatment with LLO to determine the minimal time required to
process and present LLO. By T cell assay, presentation of
LLOWT and LLOW492A by BMM was found as early as 15 min
post-uptake (Fig. 5E). The enhancement in presentation was
already detectable by 15 min, became more pronounced by
30 min (Fig. 5F), and peaked between 60 min (Fig. 5G) and
120 min post-treatment (Fig. 5H). Similar results were obtained
with BMDC (not shown). Therefore, by two independent
measures, LLO was rapidly internalized, processed and presented
on the surface of APC.
Processing and presentation of LLO to CD8 T cells
LLO provides epitopes for presentation on the class I-MHC
pathway following in vivo infection with L. monocytogenes [29]. We
tested if the LLO could be processed and presented to CD8 T cells
in vitro. For these experiments, the LLO(91–99) peptide presented
by the class I MHC protein H-2Kd was examined [19].
Presentation of LLOWT induced weak activation of the
LLO(91–99)-responsive CD8 T cell hybridoma (Fig. 6A–B). In
contrast presentation of LLOW492A and LLOWW was stronger
and the half-maximal response dose was higher than for the
LLO(91–99) peptide (Fig. 6A–B). It was not surprising that
LLOWT was not well presented because the doses required to
elicit CD8 T cell responses to LLOW492A and LLOWW was in
the range where LLOWT caused cytolysis and apoptosis of
nucleated cells (,1–10 nM, Figs. 1, 3, and 4). CD8 T cell
activation was elicited with as little as ,1 nM LLO presented by
macrophage cell lines (not shown) and,10 nM LLO presented by
PEC and BMDC (Fig. 6A–B). CD8 T cell hybridomas against
LLO also responded to L. monocytogenes-infected DC at MOI
ranging from 0.1 to 5 (Fig. 6C).
Figure 4. Antigenicity of LLO to CD4 T cells is independent of cytotoxicity. A–B. C57BL/6 BMDC (56104) and the LLO-specific hybridomas
(56104) (A) 57-3 or (B) LL73 were incubated with the indicated concentrations of LLO variants or the peptides for ,16 hrs and T cell activation was
determined. C. The half-maximal dose of antigen required to activate T cell hybridomas in 62 independent assays was calculated using non-linear
regression fitting of the dose-response plots. The plot shows the log10 of the computed half-maximal activation value. Each dot represents and
individual T cell assay. The geometric mean is given for each column. p values were calculated by student T test following validation of normal
distribution through D’Agostino & Pearson omnibus normality test. There was a statistical significance in the reduced dose requirement for
presentation of LLOWT, LLOW492A, and LLOWW when compared to LLO(190–201) or LLO(185–207) peptides (p,0.0001). D. B10.BR PEC (105) and
the 3A9 T cell hybridoma specific for HEL(48–62) (56104) were incubated with either HEL(48–62) peptide or LLO(HEL48–65) fusion protein for,16 hr.
and tested for T cell activation by CTLL-2 assay. For (A), (B), and (D) dots represent the mean6S.D. for triplicate values at each antigen dose.
doi:10.1371/journal.pone.0032310.g004
LLO as an Immunogen
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In vivo response to LLO immunization
LLOWT, LLOWW or LLO(190–201) were emulsified in
incomplete Freund’s adjuvant (oil:water emulsion) and injected
into the footpads of C57BL/6 mice. An IFNc and IL-2 was
elicited with 250 picomoles per injection from both protein and
peptide immunizations (Fig. 7). The average number of spots per
million lymph node cells that produced IFNc was 226, 740, and 84
for LLOWT, LLOWW and LLO(190–201) (Fig. 7A). In the case
of IL-2, the averages were 216, 438, and 240, for LLOWT,
LLOWW and LLO(190–201), respectively (Fig. 7B). These
responses were higher than those obtained with regular protein
antigens (ovalbumin and hen-egg lysozyme).
Discussion
We have shown that purified recombinant LLO was processed
and presented to CD4 T cell hybridomas at picomolar antigen
concentrations. The ability of LLO to be presented to CD4 T cells at
such low concentrations was not a peculiarity of the LLO peptides
that were selected for processing. Fusion of an HEL(45–65) peptide
to the amino terminus of the LLO protein led to similar
enhancement in presentation. We also found presentation of LLO
to CD8 T cell hybridomas, albeit at nanomolar levels. The enhanced
presentation of LLO was independent of its cytotoxic qualities.
Mutants of LLO that caused reduced cytolysis and apoptosis had
equivalent enhancement in presentation to the wild-type protein.
Figure 5. Binding, uptake and catabolism of radiolabeled LLO. A. BMM (106) were treated with ,150 ng of 125I-LLO or HEL for 30 min. on
ice. The amount of CPM bound to cells or found in the supernatant was measured and a percent of total bound to cells was calculated. B. 125I-LLO,
LLOW492A, or HEL (,50 ng) were given to BMM for 15, 30, or 60 min. and the amount of incorporation of radioactivity was measured. Values are
plotted as a percent of total input radioactivity that was taken by the cells. C–D. BMM (106) were treated with 50 ng 125I labeled LLOWT (C) or
LLOW492A (D) for the indicated times. Then, TCA precipitation was performed and the amount of total radioactivity present in the precipitate (ppt)
or supernatant (sol) was measured. The ppt fraction contains large polypeptides and represents the non-catabolized fraction and the sol fraction
contains small peptides and free amino acids and represents the catabolized fraction. Similar uptake and catabolism results were obtained with
BMDC. Each experiment in (A–D) is representative of at least two independent experiments performed in triplicate. E–F. BMM (105) were
incubated with LLO(190–201 peptide), LLOWT, or LLOW492A at the indicated antigen concentrations for 15 (E), 30 (F), 60 (G) or 120 (H) min. BMM
were fixed with PFA, quenched with lysine, washed and then LLO specific 57-3 T cell hybridoma (56104) was added for ,16 hr. T cell activation
was determined by CTLL-2 assay. Experiment is representative of 2 independent experiments performed in triplicate. Similar results were obtained
with BMDC.
doi:10.1371/journal.pone.0032310.g005
Figure 6. Antigenicity of LLO to a CD8 T cell was not dependent on cytotoxicity. A–B. H-2Kd-restricted LLO(91–99)-specific hybridoma
206.15 (56104) were incubated for ,16 hr. with 105 PEC (A) or 56104 BMDC (B) from BALB/c mice and various concentrations of either LLOWT,
LLOW492A, LLOWW, or LLO(91–99). C. 206.15 (56104) was incubated with the BMDC (105) infected at the indicated MOI of L. monocytogenes EGD
strain [45]. Following all incubations, T cell hybridoma activation was determined by CTLL-2 assay. All T cell activation assays are representative of at
least two independent experiments performed in triplicate. Points indicate the mean6S.D.
doi:10.1371/journal.pone.0032310.g006
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The relationship between immunogenicity and cytolysis ex-
plains previous studies in which LLO was shown to be an
ineffective immunogen or an inhibitor of T cell activation
[17,23,30–31]. At micromolar concentration, LLO leads to
immediate cytolysis. But LLO can also induce apoptosis of
lymphocytes and APC at high nanomolar concentrations [22]. It
can also cause T cell unresponsiveness to other model antigens
through an undefined effect on both APC and T cells [30–31].
Therefore, the amount of LLO that needs to be provided to T cell
assays needs to be carefully titrated over a wide range to get the
most meaningful result. Our experimental approach has been the
first one to consider these parameters in examining LLO as an
antigen.
LLO was internalized very rapidly by APC. Likewise,
processing and catabolism was rapid, presentation occurred by
15 min after uptake, with maximal presentation at about 2 hrs.
These early times indicate presentation by class II-MHC
molecules before there was any signs of cytotoxicity or escape of
contents into the cytosol. After 2 hours, and peaking at 4 hours of
LLO treatment, there was release of vesicular dextran into the
cytosol of cells. The detection of cytosolic dextran coincided with
the earliest markers of apoptosis that were detectable on BMM or
BMDC. Peak BMM/BMDC apoptosis occurred at ,6 hours
post-LLO treatment. Catabolic products of LLO were detected
within 30 minutes of treatment, and LLO was maximally
degraded by ,6 hours of treatment.
We hypothesize that three of LLO’s important biological
activities: 1) high affinity membrane binding, 2) pH dependence,
and 3) rapid catabolism contribute to its antigenicity. The
immunogenicity of LLO to both CD4 and CD8 T cells can be
maintained despite mutations that reduce the pre-pore to pore
transition, and by extension toxicity (LLOW492A and LLOWW).
There are residues of CDCs/LLO responsible for high-affinity
cholesterol binding (Loop containing regions (LC) 1–3) [32,33]. It
is possible that altering LLOs avidity to cholesterol (by mutating
LC regions) could reduce CD4 or CD8 presentation by either
decreasing entry into cells or altering subcellular localization.
Altering the pH dependence of LLO (using mutations such as
L461T) might allow LLO to lyse endocytic vesicles before they
acidify [34]. This might force LLO to become cytosolic and not
enter the late lysosomal compartments, thereby reducing its
presentation to CD4 without affecting CD8. Alternatively,
removing the pH sensor for LLO may make it non-immunogenic
because it would be immediately toxic at the cell surface and never
get internalized. Finally, the amino terminus PEST-like sequence
of LLO has been reported to undergo multiple post-translational
modifications [13,16,35]. These modifications somehow regulate
LLO stability and catabolism in the cytosol. Alterations in the
PEST-like sequence may reduce the availability of LLO peptides
to the MHC-I pathway. Ultimately, it will be interesting to
determine if adding individual elements of LLO, such as the
PEST-like sequence, LC-region, or the undecapeptide platform,
allows for targeting of ectopic antigens to specific processing and
presentations pathways.
The interactions of LLO with plasma membrane proteins are
not entirely known. We have not excluded the possibility of
receptor-mediated entry. Although LLO has been shown to trigger
TLR4 signaling, binding affinity and direct interaction between
LLO and TLR4 has not been determined [36]. Our results using
Tlr42/2 and Myd882/2 cells indicate that the TLR pathway did
not play a role in the enhanced antigenicity of LLO in vitro.
Another member of the CDC family, intermedilysin, has been
shown to bind the complement regulatory protein CD59 [37],
demonstrating that receptor binding by a CDC is a possibility.
The CDCs belong to a conserved superfamily of proteins that
includes the complement and perforin proteins, all of which are
highly regulated at the cell surface [38]. Although LLO does not
bind to CD59, it is possible that it binds other receptors involved in
complement regulation, which could accelerate its internalization
and/or colocalization with class II-MHC bearing vesicles
compartments.
An issue with CDC field is their transition from a membrane-
associated CDC to the formation of a functional pore. Based on
our current understanding, CDCs should bind to membranes
loosely, form a pre-pore complex, and at sufficient CDC density
form the final functional pore [39]. The antigenicity of LLO was
found at concentration levels sufficient for pre-pore formation but
at levels that preceded the fully functional pore. Our mutants in
the tryptophan platform support this conclusion since they should
be unable to form functional pores on the surface of cells [40].
Taken together, these data suggest that there is a functional
domain(s) of LLO distinct from its pore-forming activity that
enhances antigenicity. We are currently investigating this
possibility.
Figure 7. ELISpot response following immunization with LLO or LLO peptide. A–B. C57BL/6 mice were immunized in the footpad with 250
picomoles of either LLOWT, LLOWW, or LLO(190–201) peptide emulsified in incomplete Freund’s adjuvant. After 7 days, draining lymph nodes were
isolated and the number of IFNc (A) and IL-2 (B) producing cells was determined by ELISpot. Recall antigen was either LLOWW at 10 nM or no
antigen. Bars represent the mean+/2SEM for 2–6 mice per group over three independent experiments. Analysis of the data using D’Agostino &
Pearson omnibus normality test followed by student t test revealed that the increase in IFNc production following immunization with LLOWW was
significant when compared to both LLOWT or LLO(190–201) immunization (p = 0.0012 for LLOWT vs. LLOWW and p,0.0001 for LLOWW vs. LLO(190–
201).
doi:10.1371/journal.pone.0032310.g007
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Finally, our data indicate that LLO potency as an antigen did
not depend on intrinsic properties of the peptide segment being
presented rather than on its handling by the APC: a peptide
attached to it was highly antigenic indicating that LLO is a potent
delivery agent for ectopic proteins. LLO-fusion proteins have been
tested as DNA vaccines, as chemical conjugates with ectopic
antigens, or as antigens carried by recombinant L. monocytogenes
[41–43]. These systems have been used to immunize in different
ways to protect from tumor challenge. However, the peculiar
affinity and trafficking of CDCs has not been exploited toward a
better understanding of antigen processing and presentation
biochemistry and cell biology.
Our findings need to be placed in the context of the natural
infection in which LLO is strong donor of peptides both to the
class I and class II-MHC pathway. How LLO becomes accessible
to phagocytes during the natural infection needs to be evaluated.
Several avenues for presentation by class II molecules are
apparent: i) in the early vesicular compartments of APC, LLO is
released and can be handled like the soluble LLO protein
examined here; indeed LLO in vesicles can be targeted by specific
antibodies indicating its availability [44–45]; ii) LLO could be
released from dying cells, a possibility that we have linked to its
lymphocyte apoptotic properties that take place in vivo [22,46].
Concerning the epitopes presented by class I MHC molecules the
logical explanation is that it results from the sojourn of the bacteria
in the cytosol. This is substantiated by the lack of activation of
CD8 responses by LLO-deficient L. monocytogenes [47]. In addition,
cytosolic LLO is targeted for post-translational modification and
rapid degradation by the host cell [13,16,35]. Peptides derived




Ethics Statement. These experiments were approved by the
Division of Comparative Medicine (DCM) of Washington
University School of Medicine (Association for Assessment &
Accreditation of Laboratory Animal Care (AAALAC) accreditation
number A3381-01). All experiments were performed under
institutional (DCM) guidelines and all efforts were made to
minimize suffering. The institutional (DCM) approval number for
these studies was protocol number 20110150.
Mutagenesis and purification of LLO
The pET29b expression vector containing the LLO sequence
was kindly provided by Dr. Daniel Portnoy (University of
California, Berkeley, CA) [34]. Site-directed mutagenesis was
performed using Quickchange Site-Directed Mutagenesis kit
(Agilent Technologies, Santa Clara, CA) following the manufac-
turer’s protocol. LLO-HEL fusion proteins were generated by
adding the sequence for nucleotide sequence encoding HEL(45–
65) to the 59 end of the LLOWT cloned in pET29b using PCR.
Mutagenesis was confirmed by sequencing of constructs at the
Washington University Nucleic Acids Core facility. All LLO
variants were purified as described previously [22,34]. For some
experiments LLO was further purified by passage over Detoxy-Gel
endotoxin removal columns (Thermo Fisher Scientific, Waltham,
MA). Endotoxin levels were determined by chromogenic Limulus
Amebocyte Lysate test following the manufacturer’s instructions
(Lonza, Basel, Switzerland). Endotoxin levels were ,1 EU/mg of
LLO protein. Purity was confirmed by SDS-PAGE followed by
Coomassie Brilliant Blue staining. Concentration was determined
using bicinchoninic acid reaction (ThermoFisher Scientific).
Generation of T cell hybridomas against LLO(190–201) or
LLO(91–99)
Mice (C57BL/6 or BALB/c) were infected intraperitoneally
with 103 colony-forming units of L. monocytogenes EGD strain.
Seven days following infection, mice were sacrificed, spleens were
removed, and single-cell suspensions were generated. Isolated
spleen cells were cultured with LLO(190–201) or LLO(91–99)
peptide for 3 days then fused to BW5147 CD4+ or CD8+ to
generate stable hybridomas using a previously described protocol
[48]. T cell hybridomas were cloned at one cell per well and then
tested for specificity to LLO(190–201) or LLO(91–99) peptides
presented by peritoneal exudate cells (PEC).
Antigen Presentation Assays
All cell culture work was performed in DMEM (Life
Technologies, Carlsbad, CA) containing 10% (v/v) fetal calf
serum (Thermo Fisher Scientific), 37uC and 5% CO2 unless
otherwise specified. BMM were prepared as described previously
[49] except that L-cell conditioned media was withdrawn at the
7th day of culture and cells were used at the 10–12th day of
culture. BMDC were prepared as in [50]. T cell assays were
performed by combining 56104 or 105 APC, 56104 T cell
hybridomas, and antigen for ,16 hr. Culture supernatants were
tested for IL-2 production by CTLL-2 proliferation assay using
3H-thymidine incorporation. For fixation experiments, BMM (105)
were allowed to internalize antigen for 15–120 min., cells were
washed 3 times in DMEM, fixed with 2% paraformaldehyde
(Sigma-Aldrich, St. Louis, MO) in phosphate buffered saline
pH 7.4 for 15 min. at 25uC, washed 3 times, then incubated with
0.2 M lysine (Sigma-Aldrich) for 30 min. at 25uC. Then, cells were
washed 3 times with DMEM/10% FCS and T cell hybridomas
(56104) in DMEM/10% FCS were added for ,16 hrs. T cell
activation was determined by CTLL-2 assay. All antigen
presentation assays were performed in 200-mL final volume in
96-well tissue culture coated flat-bottom plates (Corning, Lowell,
MA). All data plotting and statistical calculations were performed
with Prism 5.0 (GraphPad Software Inc., La Jolla, CA).
To determine in vivo responses to LLO, mice were immunized
with 250 pmol of LLOWT, LLOWW or LLO(190–201) in 1:1
oil:saline emulsion (incomplete Freund’s adjuvant:0.9% pyrogen-
free saline) in the footpads. Seven days later, mice were sacrificed
and popliteal lymph nodes were isolated and dispersed. Cells were
plated on cytokine capture antibody pre-coated Multiscreen-IP
plates (Millipore, Billerica, MA) with or without recall antigen
(LLOWW at 10 nM) for 16 hours. ELISpot assay was then used to
determine the number of interferon-c (IFNc) and interleukin-2
(IL-2) producing cells (BD Biosciences, San Diego, CA). ELISpot
assay was performed following the manufacturer’s specifications
(BD Biosciences). ELISpot plates were scanned and spots were
enumerated using CTL-ImmunoSpot S5 Analyzer (C.T.L.,
Shaker Heights, OH).
LLO and HEL radiolabeling, binding, uptake and
catabolism
LLO and HEL were radiolabeled with 125I using the
chloramine-T method [51]. For cell surface binding experiments,
46105 BMM were incubated with ,150 ng of LLO or HEL
(specific activity ,76103 CPM/ng protein) in 200 mL of DMEM/
1% FCS in 1.7 mL siliconized tubes for 30 min. on ice. Cells were
spun through oil, and radioactivity was counted in the supernatant
versus cellular fraction (60%/40% dibutyl phthalate/dioctyl
phthalate, vol/vol; Thermo-Fisher Scientific). For uptake exper-
iments, 26106 BMM were incubated with 50 ng LLO or HEL
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(specific activity ,2–56103 CPM/ng of protein) in 1 mL
DMEM/10% FCS for 15 min at 25uC. Cells were centrifuged
and washed twice with DMEM/10% FCS and plated in 1 mL
volume for 0–60 min. at 37uC. At different, times cells were
removed and spun through oil to remove free radioactivity. For
catabolism experiments, the same protocol was followed except
that at the appropriate times, cells and media were harvested
separately and adjusted to 10% trichloroacetic acid (TCA; Sigma-
Aldrich) to precipitate protein. TCA precipitate was centrifuged
for 30 min. at 10,000 RCF, and the amount of radioactivity in the
pellet (proteins) and supernatant (small peptides and free amino
acids) was determined. The amount of radioactivity in all fractions
was determined using a gamma counter (LKB Wallac 1272
CliniGamma, Perkin Elmer Inc., Waltham, MA).
Immunofluorescence of dextran location
For FITC-dextran treatment, 105 BMM adhered to 12-mm
glass coverslips were treated with 0.5 mg/mL FITC-dextran (Life
Technologies) in DMEM/1% FCS for 30 minutes. Cells were
then washed 3 times with DMEM/1% FCS and incubated with
LLO in DMEM/1% FCS or left untreated for 4 hr. Following
incubation, cells were washed with 1 mL PBS 3 times, fixed with
0.5 mL of 2% PFA in PBS, washed 3 times with 1 mL DMEM/
10% FCS, washed 3 times with 1 mL PBS, then mounted to a
slide with Prolong Gold. Images were acquired using either an
Olympus BX51 (Olympus, Center Valley, PA) with a 100W
mercury source or a Zeiss Axiovert 100M microscope with a
LSM510 source (Carl Zeiss, Inc., Thornwood, NY). On the BX51,
a UPlanFl 606/1.25 objective was used. On the Axiovert 100M
either a 406/1.3 FLUAR or a Plan Apochromat 636/1.4
objective was used. Spot Advanced (Diagnostic Instruments, Inc.,
Sterling Heights, MI) was used to acquire epiluminescence images
on the BX51. LSM510 Version 3.2 (Carl Zeiss, Inc.) software was
used to acquire/analyze images and determine colocalization of
LLOWW with MHC II on the Axiovert 100M/LSM510.
Quantification of pixel density and particle size was performed
with ImageJ (NIH, Bethesda, MD). Images were thresholded using
the default setting then the analyze particle feature was used to
calculate pixel number and size of particles in multiple fields.
Microscopy images were resized and adjusted for brightness and
contrast using Adobe Photoshop CS4 (Adobe Systems Inc., San
Jose, CA).
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